{"name":"Zydus Lifesciences","slug":"zydus","ticker":"ZYDUSLIFE.NS","exchange":"NSE","domain":"zyduslife.com","description":"Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Primarily engaged in the manufacturing of generic drugs, the company ranked 100th in the Fortune India 500 list in 2020.","hq":"Ahmedabad, India","founded":0,"employees":"27917","ceo":"Sharvil Patel","sector":"Generics / Vaccines / Specialty","stockPrice":991.7,"stockChange":52.45,"stockChangePercent":5.58,"marketCap":"$10.4B","metrics":{"revenue":3200000000,"revenueGrowth":30.3,"grossMargin":72.4,"rdSpend":0,"netIncome":515705967.2561009,"cash":738147476.8483124,"dividendYield":1.17,"peRatio":20.2,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Januvia","genericName":"SITAGLIPTIN","slug":"sitagliptin","revenue":3200000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2006-01-01","label":"Januvia first approved","drug":"Januvia","drugSlug":"sitagliptin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Eliquis (apixaban) patent cliff ($1.4B at risk)","drug":"Eliquis (apixaban)","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Seroquel (quetiapine) patent cliff ($1.1B at risk)","drug":"Seroquel (quetiapine)","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":3200000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Januvia","genericName":"SITAGLIPTIN","slug":"sitagliptin","indication":"Diabetes mellitus type 2","status":"marketed","revenue":3200000000}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Pertuzumab (Perjeta®)","genericName":"Pertuzumab (Perjeta®)","slug":"pertuzumab-perjeta","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"},{"name":"Pertuzumab (ZRC-3277)","genericName":"Pertuzumab (ZRC-3277)","slug":"pertuzumab-zrc-3277","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Desidustat Oral Tablet","genericName":"Desidustat Oral Tablet","slug":"desidustat-oral-tablet","indication":"Anemia in chronic kidney disease patients not on dialysis","status":"phase_3"}]}],"pipeline":[{"name":"Januvia","genericName":"SITAGLIPTIN","slug":"sitagliptin","phase":"marketed","mechanism":"Januvia works by blocking an enzyme that breaks down hormones that help the body release insulin.","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Desidustat Oral Tablet","genericName":"Desidustat Oral Tablet","slug":"desidustat-oral-tablet","phase":"phase_3","mechanism":"Desidustat inhibits prolyl hydroxylase domain-containing protein (PHD) enzymes to stabilize hypoxia-inducible factor (HIF) and increase endogenous erythropoietin production.","indications":["Anemia in chronic kidney disease patients not on dialysis","Anemia in dialysis-dependent chronic kidney disease patients"],"catalyst":""},{"name":"Pertuzumab (Perjeta®)","genericName":"Pertuzumab (Perjeta®)","slug":"pertuzumab-perjeta","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"Pertuzumab (ZRC-3277)","genericName":"Pertuzumab (ZRC-3277)","slug":"pertuzumab-zrc-3277","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive gastric or gastroesophageal junction cancer"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Zydus Lifesciences receives FDA approval for generic version of Eliquis","summary":"Zydus Lifesciences has received approval from the US FDA for its generic version of Eliquis, a blood thinner used to prevent stroke and blood clots.","drugName":"Eliquis (apixaban)","sentiment":"positive"},{"date":"2023-08-11","type":"earnings","headline":"Zydus Lifesciences reports strong Q2 earnings","summary":"Zydus Lifesciences has reported strong earnings for the second quarter of 2023, with revenue growth of 15% year-over-year.","drugName":"","sentiment":"positive"},{"date":"2023-05-25","type":"deal","headline":"Zydus Lifesciences partners with Biocon to develop biosimilars","summary":"Zydus Lifesciences has partnered with Biocon to develop biosimilars, a type of biologic medicine that is similar to a reference product.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOWHRwTGxhaHZJbk5OQjViVUQ3ZmkwRjdMalNDT1AzOHpSOGdEb29hY21GSmlhWXhrdFFUMFJhOTJzR0Y0RDlkbzduVjZiQVZ4Sy1yODVfTjdQRVctazYtRmg1NmhjWUVCamt2QVhZNk1Wa25hVUFzNHdxVjQ5cUNfcEp4bDVDWDNySkdKZ3g4a0ZSTHVLX2NZLUtFNEY5aVB5WWVGY28wQnZMR1RsV0FUX2NBcXBQWVR1ZWc5enNzOS11M2NHczc1Xzg3NWdEQUl1d3R0UHVGWlVyZTlBUVJ3?oc=5","date":"2026-03-20","type":"regulatory","source":"Whalesbook","summary":"Semaglutide Patent Expiry: India mein Generic Drugs ka Toofan! Prices **70%** tak girne ka chance - Whalesbook","headline":"Semaglutide Patent Expiry: India mein Generic Drugs ka Toofan! Prices **70%** tak girne ka chance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPdHY1dzZ0Y2dwYmh3RWE3d09ROGRmQWhYOFBRVURDOG9idGx1MnMxbzZfOHowMXFSOVZMNUp1cG9aT1YxeFd0UjFXeXpfV3lQdGRiVm5EU2tZUlZiN3JXV1NKd201TGRyb3dFMmw2dHBNWDVoTUZjVy1jV2VkdWJqMm9ld3hZdDJVWkRjdnBxVEVyZjJRNE9VRjJmc2hwbnM4aDFwWjY4TS1sMlpOWk9KTmhCdTBONlRNbjlwWGlLUzN4VkJKQ1Q1TWZweVRMbTZRUEJESGpxNVl2MnFoNkE?oc=5","date":"2026-03-20","type":"regulatory","source":"Whalesbook","summary":"India's Drugmakers Rush Generic Semaglutide After Patent Expiry - Whalesbook","headline":"India's Drugmakers Rush Generic Semaglutide After Patent Expiry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPX3lBcEgwM2ZNYkZOX1VuVFgzVmh1WE9LVl9LSXFUdERSMzJMSFYzQnhMWE1yYm5UdjRoUEVwZjRXX1BxYTNMUjRBOHNkQy1Zc3YyVFEwaXoxcFJpMGRJZDU4ZUROX1QzbzlMVkdscDZLSTZKanJKUTd6YnZncTlUeGZCRkxnVE5TWkxzcHZrLU9wZXQwX3BBeXNNcE5VNE1TdXNRemJQRnc0TG5vVTFqaUNFRmFKRzMtNXo0dkZ2NlBRa29wd3dsVzFfWQ?oc=5","date":"2026-02-12","type":"pipeline","source":"Reuters","summary":"India's Zydus Life agrees $120 million settlement with Astellas over bladder drug - Reuters","headline":"India's Zydus Life agrees $120 million settlement with Astellas over bladder drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPUUNZSHM5dE51X3lsLXR5SURFSlpraDR3b2h0cDNLaW1oQ2ZSQlk2by1iUkl6d0dEdkJDQ3VlMDZIYkdES1V0OTRtWXVBZnJ3Zng3NVp2eGJGWVQ1Qy0wZUFLam5VY0ZQd3pyWlBpTlFzMEFhWVF2dUo3VUpfbHh2R0dlelBJYmc?oc=5","date":"2025-11-26","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market - Yahoo! Finance Canada","headline":"Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFA3cTVsei02cDVyLXJxZlV4eXdId043c0YtUWpGYkEyVVNqTi1HNTRnczlCNkVhWXFQbmlFWU03VEkzNG1JYzVZYXJXa3FwcWlfd2tEVEQ5YTR1QkZtblBqU2Q5TFFDUWlQaUxkUkc0anJxX2FZX2V6ag?oc=5","date":"2025-11-25","type":"pipeline","source":"Quiver Quantitative","summary":"Xtrackers Nifty 500 India ETF Holdings - Quiver Quantitative","headline":"Xtrackers Nifty 500 India ETF Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQWZQaWdGNW5VelVVTmlXbzc0ZEVPQWoxenJYcUFoNl9GblRNTk4xc0hJeGpGemwyeWFPRHBEZDdkZ2VDRE5ObHJsLXFNSnRUNUVZaVY0YmtSMlNDajlHVXl0OElFa0VDQzN3RDk3T2RqcDBMMi1sUlp1Yzc1TUxuQ080MGlJa3Ns?oc=5","date":"2025-05-08","type":"regulatory","source":"Yahoo Finance","summary":"Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes - Yahoo Finance","headline":"Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNWHpxbnlqVWVEOWExS282bWhyd25TSkZmWEh3MDVLVFl5czh6NDZxVnFZZGcwVXIzZGRONjBFQnlGSzBIOVBQdXMtZnNqVlhQakJTREpIUUlaZ0hhbFVkSWtxQmFlcVpDVGhneTEwZ1RsOVJ3UmQ5ZC1CY0FmVkROOGJuVVZBM0gx?oc=5","date":"2025-03-11","type":"deal","source":"Yahoo Finance Singapore","summary":"India's Zydus Lifesciences to buy 86% stake in French medical devices maker - Yahoo Finance Singapore","headline":"India's Zydus Lifesciences to buy 86% stake in French medical devices maker","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNSFhzQ1Ryb1NCbzV2WGhhX3E4Vk1IY3Rqa2lBdm4wLW9GQjJaNlZ3YWJJMjdNSDVvWDBmQmpJMEd1Tjh4WmdmTncyOU04cF81RVphWDJuNWZOaVBaOHY5T1ZFVElncmxvWk11RTZzVlQ1NDFVNXFSYWlZQnZkWlJWSDdQaWJfenNJRGU1MDM5aW1NTjZKMlYzcw?oc=5","date":"2024-10-17","type":"trial","source":"Yahoo Finance Singapore","summary":"Cipla Limited (CIPLA.NS) stock historical prices and data - Yahoo Finance Singapore","headline":"Cipla Limited (CIPLA.NS) stock historical prices and data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE4ta1Y1WnNPcjA3ckwyRnFqUS11ekVaczNTWXdqclRHMXNjZ3dvS0gtYUl5YUlNS2hybHdWWlQ0Slpkd2JkVVRtZV9waG1nWkZZbTd0bXlSWTBsdXRIWUE?oc=5","date":"2018-07-13","type":"pipeline","source":"Yahoo Finance UK","summary":"Abbott India Limited (ABBOTINDIA.NS) stock price, news, quote and history - Yahoo Finance UK","headline":"Abbott India Limited (ABBOTINDIA.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE0wNFJ4bTl3dlZYdnBiSklRRExCRU1xa3lFSG5DRkhGNy1JaHU0QkRsWC1YVUhGeVFFTDU4bVo1RldVWXF1cGd4MFRUWS1hLXk2TGVDTEl3N1dMa0FyVWc?oc=5","date":"2017-08-24","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Abbott India Limited (ABBOTINDIA.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Abbott India Limited (ABBOTINDIA.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA1R0FpMWtiU2dKZjk1SW9UVURoazh0cnR5WUp2bWk4NFBTVUNxTkd3Qmp6ZFBvSU1pWU4xaWlFTVQzT05zSUpwd25iemFqSDJpTGxJY1dEaEF2REo4U3I3Z3hieW56Tmx4?oc=5","date":"2017-07-17","type":"pipeline","source":"Yahoo Finance Singapore","summary":"NATCO Pharma Limited (NATCOPHARM.NS) company profile and facts - Yahoo Finance Singapore","headline":"NATCO Pharma Limited (NATCOPHARM.NS) company profile and facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE52Rmh5MGJHY1BQSm92dG9xSDFoQ0xXQ3diekY5Q054YjEwQUlfWEFOOVFXaXB2cFV3UEF2dGI1UzJRcl9NUllwdFMyYVFLWjZOYnBZUlUwNE1ZSE1kSlE?oc=5","date":"2017-06-15","type":"pipeline","source":"Yahoo Finance Australia","summary":"Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Eliquis (apixaban)","drugSlug":"apixaban","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Seroquel (quetiapine)","drugSlug":"quetiapine","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":4,"phaseCounts":{"marketed":1,"phase_3":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sun Pharmaceutical Industries","Dr. Reddy's Laboratories","Cipla Limited"],"therapeuticFocus":["Oncology","Infectious Diseases"],"financials":{"source":"yahoo_finance","revenue":2357330917.212,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":2357330917.212},{"period":"2024-03-31","value":1986372256.41},{"period":"2023-03-31","value":1762510510.172},{"period":"2022-03-31","value":1548412757.624}],"grossProfit":1661173831.276,"grossProfitHistory":[{"period":"2025-03-31","value":1661173831.276},{"period":"2024-03-31","value":1307550175.3140001},{"period":"2023-03-31","value":1077579406.286},{"period":"2022-03-31","value":940758181.338}],"rdSpend":19778613.956,"rdSpendHistory":[{"period":"2025-03-31","value":19778613.956},{"period":"2024-03-31","value":16269841.892},{"period":"2023-03-31","value":14181287.092},{"period":"2022-03-31","value":11967419.004}],"sgaSpend":315444874.218,"operatingIncome":624404785.7820001,"operatingIncomeHistory":[{"period":"2025-03-31","value":624404785.7820001},{"period":"2024-03-31","value":474018397.408},{"period":"2023-03-31","value":297911456.672},{"period":"2022-03-31","value":258364671.534}],"netIncome":472587737.37,"netIncomeHistory":[{"period":"2025-03-31","value":472587737.37},{"period":"2024-03-31","value":403038862.53000003},{"period":"2023-03-31","value":204709698.722},{"period":"2022-03-31","value":468598597.702}],"eps":44.97,"epsHistory":[{"period":"2025-03-31","value":44.97},{"period":"2024-03-31","value":38.14},{"period":"2023-03-31","value":19.3},{"period":"2022-03-31","value":43.83}],"cash":86340855.432,"cashHistory":[{"period":"2025-03-31","value":86340855.432},{"period":"2024-03-31","value":43128656.62},{"period":"2023-03-31","value":50939851.572000004},{"period":"2022-03-31","value":68692567.372}],"totalAssets":3884889455.158,"totalLiabilities":1132341313.142,"totalDebt":335547214.168,"equity":2501368098.994,"operatingCashflow":707675465.658,"operatingCashflowHistory":[{"period":"2025-03-31","value":707675465.658},{"period":"2024-03-31","value":333782385.362},{"period":"2023-03-31","value":280785307.312},{"period":"2022-03-31","value":219768178.83}],"capex":-178842947.524,"capexHistory":[{"period":"2025-03-31","value":-178842947.524},{"period":"2024-03-31","value":-94674189.084},{"period":"2023-03-31","value":-107654557.16600001},{"period":"2022-03-31","value":-125584800.124}],"freeCashflow":528832518.134,"dividendsPaid":-31589391.35,"buybacks":0,"employees":27917,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":154897666.742,"ebitda":192449882.046,"period":"2025-12-31","revenue":708061848.296,"epsBasic":10.36,"netIncome":108824147.854,"rdExpense":null,"epsDiluted":10.36,"grossProfit":516301189.334,"operatingIncome":134962411.176},{"sga":null,"ebit":209408947.022,"ebitda":234273191.916,"period":"2025-06-30","revenue":675334194.58,"epsBasic":14.58,"netIncome":153174609.032,"rdExpense":null,"epsDiluted":14.58,"grossProfit":488460753.85,"operatingIncome":187270266.142},{"sga":null,"ebit":175041777.78800002,"ebitda":199885137.134,"period":"2025-03-31","revenue":656871370.148,"epsBasic":null,"netIncome":122274440.766,"rdExpense":null,"epsDiluted":null,"grossProfit":445352982.778,"operatingIncome":201232254.98},{"sga":null,"ebit":126994574.61400001,"ebitda":150908527.074,"period":"2024-12-31","revenue":535035525.89,"epsBasic":10.17,"netIncome":106881791.89,"rdExpense":null,"epsDiluted":10.17,"grossProfit":369684642.374,"operatingIncome":101921474.24},{"sga":null,"ebit":135338351.04,"ebitda":159732671.104,"period":"2024-09-30","revenue":534001691.264,"epsBasic":9.06,"netIncome":95154556.68800001,"rdExpense":null,"epsDiluted":9.06,"grossProfit":380346714.628,"operatingIncome":123475359.77600001}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":991.7,"previousClose":939.25,"fiftyTwoWeekHigh":1059.05,"fiftyTwoWeekLow":835.5,"fiftyTwoWeekRange":"835.5 - 1059.05","fiftyDayAverage":908.4,"twoHundredDayAverage":939.58,"beta":0.32,"enterpriseValue":10425390080.872416,"forwardPE":23.7,"priceToBook":3.94,"priceToSales":3.82,"enterpriseToRevenue":3.83,"enterpriseToEbitda":13.72,"pegRatio":0,"ebitda":759980748.8611615,"ebitdaMargin":27.9,"freeCashflow":0,"operatingCashflow":0,"totalDebt":1006276112.6654607,"debtToEquity":34.3,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":29,"targetMeanPrice":985.41,"targetHighPrice":1140,"targetLowPrice":800,"dividendRate":11,"payoutRatio":0.22,"fiveYearAvgDividendYield":0.83,"exDividendDate":1753401600,"insiderHeldPercent":75.2,"institutionHeldPercent":13.9,"sharesOutstanding":1006233990,"floatShares":249470290,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":49.03,"epsForward":41.81,"revenuePerShare":259.26,"bookValue":251.49,"officers":[{"age":46,"name":"Dr. Sharvil Pankajbhai Patel","title":"MD & Executive Director"},{"age":null,"name":"Mr. Punit  Patel","title":"President & CEO of America"},{"age":54,"name":"Mr. Tushar Dhansukh Shroff","title":"President of Finance & CFO"},{"age":null,"name":"Mr. Arvind  Bothra","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Dhaval Narendra Soni","title":"Company Secretary & Compliance Officer"},{"age":64,"name":"Mr. Nitinkumar Dalsukhray Parekh","title":"President of Special Projects"},{"age":51,"name":"Mr. Vikram  Shukla","title":"President of Parenteral Operations"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://zyduslife.com","phone":"91 79 4804 0000"}}